Abstract
Warby Parker Inc. will report results on November 5, 2026 Pre-MKt, and this preview reviews last quarter’s performance, current-quarter expectations for revenue and earnings, and how product mix, services expansion, and channel execution could shape the print and guide.Market Forecast
Based on the latest projections, the current quarter’s revenue is estimated at 245.06 million US dollars, implying year-over-year growth of 9.16%, while adjusted EPS is projected at 0.10 with a year-over-year increase of 18.95%; EBIT is estimated at 13.37 million US dollars with year-over-year growth of 13.70%. Forecasts for gross margin and net profit margin are not disclosed, but the trajectory of mix and services expansion points to stable-to-improving profitability versus the prior-year period.The main business continues to be eyewear products supported by a balanced price and mix strategy and disciplined omnichannel execution across stores and digital platforms. The most promising segment remains the services-led portion of the model, particularly eye exams and vision services, which expanded across roughly nine-tenths of the store base and delivered about 30% year-over-year growth; eye-care category revenue related to this area was 17.15 million US dollars last quarter, underscoring the expanding services attachment opportunity.
Last Quarter Review
In the previous quarter, Warby Parker Inc. reported revenue of 235.51 million US dollars, a gross profit margin of 52.93%, GAAP net profit attributable to shareholders of 4.64 million US dollars, a net profit margin of 1.97%, and adjusted EPS of 0.16, increasing 30.08% year over year. A notable highlight was the return to GAAP profitability with quarter-on-quarter net profit growth of 46.18%, reflecting improved operating leverage and stronger contribution from higher-margin product features. The main business delivered steady momentum, with eyewear products revenue at 191.76 million US dollars as part of a company-wide year-over-year revenue increase of 9.81%, and the services and eye-care categories benefiting from expanding exams coverage and customer add-ons.Current Quarter Outlook
Mainline Eyewear and Omnichannel Execution
For the core eyewear category, which contributed 191.76 million US dollars last quarter, the setup into the current quarter centers on sustained unit growth, a healthy mix of higher-value lens options, and continued channel productivity. The prior quarter’s 52.93% gross margin benefited from product mix that favored progressives and lens enhancements, and from price architecture tuned to perceived value; these same factors are poised to influence current-quarter profitability. Execution across the store fleet and digital channels remains essential to conversion and average order value, and the updated marketing posture following the wind-down of the legacy home-try-on program has lowered the sales expense ratio while shifting spend to channels with higher measured return. Management has also emphasized operational improvements in lens fulfillment and supply chain processes, which should support service levels during seasonal demand pockets and can temper cost volatility from logistics or input headwinds. Taken together, steady traffic, careful inventory and assortment management, and mix uplift from premium lens features establish a constructive backdrop for mid-to-high single-digit revenue growth and incremental operating leverage versus the prior year.On the margin front, the company faces moving pieces that can work in both directions. Headwinds cited around tariffs and optical lab and freight costs were present earlier in the year, though some were offset by pricing actions and richer attachment of higher-margin lenses and coatings. If pricing discipline remains intact and the mix of progressives and lens enhancements holds, the consolidated gross margin could remain resilient even in the absence of a formal margin guide. The net profit margin profile, at 1.97% last quarter, leaves room for expansion through continued SG&A efficiency, particularly if marketing efficiency gains persist and in-store productivity trends remain favorable. A key watch item for investors this quarter will be whether these efficiencies are durable enough to translate the revenue growth estimate of 9.16% year over year into a comparable or better improvement in earnings metrics.
The omnichannel model is also leveraging insurance practices to improve conversion. Internal tools for out-of-network submissions and increased in-network insurance penetration have supported customer spend consistency. With insurance-eligible purchases often linked to comprehensive visits and premium lenses, further productivity gains in this area could contribute to both revenue and margin this quarter. The cadence of store openings and maturing cohorts in newer markets will also determine same-store momentum, while the digital experience—supported by AI-enabled virtual try-on and personalized recommendations—continues to drive an improved conversion funnel online.
Eye Exams and Vision Services
Eye exams and related vision services have emerged as a scalable, compounding engine within the model, with year-over-year growth of roughly 30% cited earlier in the year and coverage now extending to around 90% of stores. This expansion is not only a traffic and retention lever but also a pathway to higher basket size as customers pair exams with eyewear purchases and lens upgrades. The category’s contribution shows up in the eye-care revenue line, which totaled 17.15 million US dollars last quarter, and in the broader uplift from services-driven attachment rates in eyewear. By deepening clinical offerings, such as retina imaging and improved optometrist efficiency tools, stores can manage appointment throughput while maintaining service quality, which drives repeat visits and strengthens the lifetime value of customers.In the current quarter, the services thesis contributes to three measurable effects. First, a predictable flow of exam appointments can smooth revenue cadence and reduce dependence on promotional activity to drive traffic. Second, it increases the opportunity to attach premium lenses and coatings, a critical variable for gross margin consistency. Third, services underpin insurance utilization, which in turn supports blended pricing and reduces friction at the point of sale. For the print, investors will look for continued growth in the exams run-rate, signs that clinical capacity is being utilized effectively without compromising customer experience, and evidence that services attachment continues to raise conversion. Alignment of services adoption with contact lenses and eyewear add-ons may show up as a tailwind to the company’s adjusted EPS trajectory, which is forecast to increase 18.95% year over year this quarter.
The forward implication is that scaling services strengthens the overall economic engine by tying together recurring care with recurring purchases. As services coverage approaches full-chain penetration, incremental gains should increasingly come from productivity—appointments per day per location, improved show rates, and cross-sell efficacy. Monitoring these operational metrics, even if qualitative, can help gauge whether services are on track to support both near-term margins and the medium-term cash generation profile.
Key Stock Price Drivers This Quarter
Three core variables are likely to drive the share price reaction around the result and guide. The first is the revenue beat-or-meet dynamic relative to the 245.06 million US dollars estimate, together with any commentary on fourth-quarter and full-year run-rate. A delivery at or above the 9.16% year-over-year revenue growth estimate would be supportive, particularly if paired with confirmation that the demand environment remains stable and that store cohorts are maturing in line with expectations. Conversely, any signal of softening conversion or delayed openings could pressure sentiment even if headline growth remains within the guided range.The second driver is the profitability path. Last quarter’s net margin of 1.97% and adjusted EPS of 0.16 set a baseline for what investors hope will be a continued climb. This quarter’s EPS estimate of 0.10 suggests seasonality and mix could modulate profitability, but if gross margin remains resilient and SG&A efficiencies persist, the quality of earnings can still impress. Watch for commentary on tariffs, optical lab costs, and freight, as well as on marketing allocation. Structural levers—such as attachment of higher-margin lenses and continued reduction of lower-return marketing programs—could be decisive in whether EBIT lands near the estimated 13.37 million US dollars and whether adjusted EPS attains the projected year-over-year expansion of 18.95%.
The third driver is optionality from product innovation and partnerships. Analysts have highlighted the potential for smart or AI-enabled eyewear as a medium-term catalyst, and recent announcements of partnerships to develop AI-powered glasses point to an emerging adjacent product line. While near-term revenue contribution is not yet embedded, any incremental disclosure on roadmap, timing, or early customer feedback can shape expectations about the slope of future growth. In parallel, progress in contact lenses attachment, insurance integration, and digital try-on functionality can reinforce durable share-of-wallet with existing customers. The stock could respond positively if management couples a solid quarter with credible commentary about these newer vectors and their path to commercial scale.
Analyst Opinions
Across the past six months, published views are predominantly bullish, with a tally of four bullish versus zero bearish notes in our screen, indicating 100% of the captured opinions are constructive; we present only the majority view here. TD Cowen’s Oliver Chen reiterated a Buy rating with a 32.00 US dollars price target, pointing to a resilient revenue algorithm supported by improving profitability and a consistent omnichannel playbook. William Blair’s Dylan Carden maintained a Buy stance, underscoring that near-term guidance remains conservative and that the prospect of a smart glasses category can serve as a future growth catalyst if execution aligns with brand and design strengths. BTIG’s Janine Stichter reaffirmed a Buy rating and a 34.00 US dollars target, emphasizing the opportunity around AI-enabled glasses and the reinforcement such a product line could provide to customer engagement and repeat purchases. Telsey Advisory Group’s Joe Feldman also maintained a Buy with a 32.00 US dollars target, framing the growth path as driven by store expansion, services penetration, and disciplined expense management.The bullish cohort generally coalesces around three pillars that are immediately relevant to the quarter at hand. The first is the reliability of mid-to-high single-digit revenue growth anchored by consistent in-store execution and enhanced digital experiences; the 9.16% year-over-year revenue estimate for the current quarter aligns with this theme. The second is profitability leverage that flows from mix, services attachment, and marketing efficiency, evidenced by last quarter’s 52.93% gross margin and the 30.08% year-over-year increase in adjusted EPS to 0.16. Analysts see room for continued EPS expansion if cost controls hold and premium lens features continue to gain share within orders. The third pillar is optionality in product innovation, where bulls see the emerging AI/smart glasses effort as a multi-year vector that can augment the core eyewear franchise and broaden the addressable use-cases for customers. While this is not expected to materially affect the current quarter’s revenue, the mere presence of a credible roadmap can support valuation if management articulates a prudent path to commercialization.
Integrating these views, the bullish case for the upcoming report rests on the company’s capability to meet or slightly exceed consensus revenue around 245.06 million US dollars, protect gross margins via mix and pricing, and extend the trajectory of adjusted earnings improvement. A confirmatory signal would be commentary that services continue to scale—eye exams and associated care having grown roughly 30% year over year earlier in the year—and that insurance penetration and contact lens attachment remain on an upward trend. In this scenario, Buy-rated analysts expect that the stock can sustain or expand its multiple as the model’s cash generation becomes more visible. Should management also outline the next milestones for smart or AI-enabled eyewear, bulls would likely view that as additive to the medium-term thesis without requiring near-term revenue contribution.
In summary, the prevailing analyst sentiment is constructive heading into November 5, 2026, with forecasts calling for year-over-year revenue growth and continued progress in earnings quality. The debate for bulls centers less on whether demand is intact and more on the pace at which services, mix, and innovation can lift profitability. If the company delivers on revenue while demonstrating disciplined expense control and offering credible updates on its product and services roadmap, the bullish camp believes the quarter can validate the operating playbook and support a favorable outlook for the remainder of the year.
Comments